Click HERE to register.

Join us for the 9th Annual International Clinical Cancer Genetics and Genomics Conference in conjunction with the Personalized Cancer Care Consortium!

This activity will provide an interdisciplinary educational forum in which to update state-of-the-art science including novel therapies for inherited cancers, discuss real-world cases, curate interesting pedigrees, and prepare case summaries to disseminate new knowledge in translational genomics and evidence-based clinical management of high-risk patients and their family members.

Target Audience

This activity is designed for physicians, physician assistants, advanced nurse practitioners, genetic counselors, oncology nurses, and other healthcare professionals currently providing oncology care and cancer genetics risk assessment services or initiating such care and services in their healthcare system. Special efforts will be made to educate clinicians practicing in geographically or socioeconomically underserved communities.

Learning Objectives

At the conclusion of this activity, participants will be able to:

• Recall advanced concepts in genetics, genomics, and next generation sequencing (NGS) technologies;
• Analyze controversies in cancer risk assessment and genetic testing including the integration of polygenic risk scores;
• Recognize how scientific advances in Lynch syndrome and other inherited solid tumors and hematologic malignancies can improve the clinical management of patients;
• Discuss how the integration of novel cancer therapies based on genomic alterations in tumor tissue may reveal germline mutations that can guide patient management;
• Recognize the limitations of genomic testing as it relates to both cancer risk as well as therapeutic selection, including variants of uncertain significance and in silico predictions;
• Identify how a globally-informed perspective on experimental therapeutics for rare cancers including immunotherapy can improve patient outcomes;
• Discuss how emerging concepts in cancer interception and cancer risk modifiers including lifestyle and chemoprevention can impact disease management strategies;
• State the ethical, legal, and social implications of genomic testing in diverse populations.